Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 230

Results For "US"

8098 News Found

Zydus and Bayer announce extension of their JV
News | June 21, 2021

Zydus and Bayer announce extension of their JV

Bayer Zydus Pharma will continue to operate in core therapies with new products in the pipeline


Jubilant HollisterStier to manufacture COVID-19 Vaccine COVAXIN in US
News | June 15, 2021

Jubilant HollisterStier to manufacture COVID-19 Vaccine COVAXIN in US

Entered into a manufacturing partnership with Ocugen, Inc. for manufacturing of COVID-19 vaccine COVAXIN for the US and Canadian markets


Zydus Cadila receives tentative USFDA approval for Brivaracetam
News | June 15, 2021

Zydus Cadila receives tentative USFDA approval for Brivaracetam

The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad


Govt. to increase Janaushadhi Kendras to 10,000
News | June 15, 2021

Govt. to increase Janaushadhi Kendras to 10,000

Under the PMBJP, all the districts of the country are covered and ensure easy reach of affordable medicine to the people in every nook and corner of the country


Sun Pharma’s US Specialty business to grow at 21% CAGR in 2 years
News | June 14, 2021

Sun Pharma’s US Specialty business to grow at 21% CAGR in 2 years

The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination


Lupin launches generic version of Brovana in US
News | June 04, 2021

Lupin launches generic version of Brovana in US

Arformoterol Tartrate Inhalation Solution is for treatment of bronchoconstriction


Zydus Cadila receives tentative approval from USFDA for lung cancer drugs
Policy | June 03, 2021

Zydus Cadila receives tentative approval from USFDA for lung cancer drugs

Osimertinib works by slowing or stopping the growth of cancer cells and binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors


Glenmark Pharmaceuticals launches Rufinamide Tablets USP, 200 mg and 400 mg
News | June 02, 2021

Glenmark Pharmaceuticals launches Rufinamide Tablets USP, 200 mg and 400 mg

The Banzel Tablets, 200 mg and 400 mg market2 achieved annual sales of approximately $285.3 million.


Jubilant to invest US $92 mn to expand sterile injectable capacity
News | June 01, 2021

Jubilant to invest US $92 mn to expand sterile injectable capacity

This investment is being made to set up a high speed 400 vials a minute injectable fill line with isolator technology


Zydus new initiative to safeguard patients against counterfeit drugs
News | May 29, 2021

Zydus new initiative to safeguard patients against counterfeit drugs

The patients can check to see if the product purchased by them is genuine or not by scratching the surface and verifying the code through the app or the website